

FOOTNOTES

- * IBM FT NR-80 80 MHz spectrometer.
- † EM Prep-10 LiChrosorb RP-18, 1 cm X 25 cm, Rainin Scientific, Woburn, MA.
- ‡ Waters Associates NOVA-PAK, Milford, MA.
- § Waters Associates C-18 μ Bondapak, 3.9 mm x 30 cm, Milford, MA.
- ¶ Hewlett Packard 3390 Integrator.

ACKNOWLEDGMENTS

The authors express their appreciation to T. K. Natarajan and F. W. Gilbert for assistance with cyclotron operation, and to M. Bryan and M. Murrell for assistance with animal studies. This investigation was supported by USPHS grants CA32845, NS15080, and MH00053.

REFERENCES

1. REISINE TD, FIELDS JZ, STERN LZ, et al: Alterations in dopaminergic receptors in Huntington's disease. *Life Sci* 21:335-344, 1977
3. LEE T, SEEMAN P, TOURTELLOTTE W, et al: Binding of ^3H -neuroleptics and ^3H -apomorphine in schizophrenic brains. *Nature* 274:897-900, 1978
4. OWEN F, CROSS AJ, CROW TJ, et al: Increased dopamine receptor sensibility of schizophrenia. *Lancet* 2:223-225, 1978
5. LEE T, SEEMAN PS: Abnormal neuroleptic/dopamine receptors in schizophrenia. In *Receptors for Neurotransmitters and Peptide Hormones*. Peper G, Kuhar MJ, Enna SJ, eds. New York, Raven Press, 1980, pp 435-442
6. SNYDER SH: The dopamine hypothesis of schizophrenia: Focus on the dopamine receptor. *Am J Psychiatry* 133: 197-202, 1976
7. MELTZER HY, STAHL SM: The dopamine hypothesis of schizophrenia: A review. *Schizophrenia Bull* 2:19-76, 1976
8. SNYDER SH: Dopamine receptors, neuroleptics, and schizophrenia. *Am J Psychiatry* 138:460-464, 1981
9. CHRISTENSEN E, MOLLER JE, FAURBYE A: Neuro-pathological investigation of 28 brains from patients with dyskinesia. *Acta Psychiatr Scand* 46:14-23, 1970
10. BARBACCIA ML, TRABUCCHI M: Tardive dyskinesia: A biological approach. In *Neurochemistry and Clinical Neurology*. New York, Alan R. Liss, 1980, pp 181-193
11. GOETZ CG, WEINER WJ, NAUSIEDA PA, et al: Tardive dyskinesia: Pharmacology and clinical implications. *Clin Neuropharmacol* 5:3-22, 1982
12. TEWSON TJ, RAICHEL ME, WELCH MJ: Preliminary studies with [^{18}F]haloperidol: A radioligand for *in vivo* studies of dopamine receptors. *Brain Res* 192:291-295, 1980
13. FOWLER JS, ARNETT CD, WOLF AP, et al: [^{11}C]Spiroperidol: Synthesis, specific activity determination, and bio-distribution in mice. *J Nucl Med* 23:437-445, 1982
14. KUMALA HK, HUANG CC, DINERSTEIN RJ, et al: Specific *in vivo* binding of ^{77}Br -p-spiroperidol in rat brain: A potential tool for gamma ray imaging. *Life Sci* 28:1911-1916, 1981
15. ZANZONICO PB, BIGLER RE, SCHMALL B: Neuroleptic binding sites. Specific labeling in mice with [^{18}F]haloperidol, A potential tracer for positron emission tomography. *J Nucl Med* 24:408-416, 1983
16. VINCENT SH, SHAMBHU MV, DIGENIS GA: Synthesis of [^{82}Br] bromperidol and preliminary tissue distribution studies in the rat. *J Med Chem* 23:75-79, 1980
17. WOLF AP, WATANABE M, SHIUE C-Y, et al: No-carrier-added (NCA) ^{18}F -spiroperidol. *J Nucl Med* 24:P52, 1983 (abst)
18. MAZIERE M, BERGER G, COMAR D: ^{11}C -Radiopharmaceuticals for brain receptor studies in conjunction with positron emission tomography. In *Applications of Nuclear and Radiochemistry*. Lambrecht RM, Morcos, N, eds. New York, Pergamon Press, 1982, pp 251-270
19. JANSSEN PAJ: U.S. Patent No. 3155670, 1964
20. GRANDGUILLLOT J-C, ROUESSAC F: Sur une voie d'accès à l'isopropényl-2 méthyl-1 cyclobutane éthanol. *C R Acad Sc Ser C* 277:1253-1256, 1973
21. LANGSTRÖM B: On the synthesis of ^{11}C -compounds. Ph.D. Thesis, Acta Universitatis Upsaliensis, Sweden, No. 555, 1980
22. GLOWINSKI J, IVERSEN LL: Regional studies of catecholamines in the rat brain-I: The disposition of [^3H]norepinephrine, [^3H]dopamine and [^3H]dopa in various regions of the brain. *J Neurochem* 13:655-669, 1966
23. DUELFER T, POGUN S, BURNS HD, et al: Synthesis and *in vitro* evaluation of spiperone analogs as potential dopamine receptor imaging ligands. *J Nucl Med* 23:P100, 1982
24. CREESE I, SCHNEIDER R, SNYDER SH: ^3H -Spiroperidol labels dopamine receptors in pituitary and brain. *Eur J Pharmacol* 46:377-381, 1977
25. COPPER JF, LEVIN J, WAGNER HN: Quantitative comparison of *in vitro* and *in vivo* methods for the detection of endotoxin. *J Lab Clin Med* 78:138-148, 1971
26. BAUDRY M, MARTRES M-P, SCHWARTZ J-C: *In vivo* binding of ^3H -pimozide in mouse striatum: Effects of dopamine agonists and antagonists. *Life Sci* 21:1163-1170, 1977
27. HOLLT V, CZLONKOWSKI A, HENRY A: The demonstration *in vivo* at specific binding sites for neuroleptic drugs in mouse brain. *Brain Res* 130:176-183, 1977
28. LADURON P, LEYSEN J: Specific *in vivo* binding of neuroleptic drugs in rat brain. *Biochem Pharmacol* 26:1003-1007, 1977
29. KUHA MJ, MURRIN LC, MALOUF AT, et al: Dopamine receptor binding *in vivo*: The feasibility at autoradiographic studies. *Life Sci* 22:203-210, 1978
30. WAGNER HN, BURNS HD, DANNALS RF, et al: Imaging dopamine receptors in the human brain by positron tomography. *Science* 221:1264-1266, 1983

Erratum

Please note page corrections for the following entries to the Table of Contents, Volume 25, Number 8, August 1984, p. 7A:

ADJUNCTIVE MEDICAL KNOWLEDGE

The Significance of Chromosomal Aberrations in Indium-111-Labeled Lymphocytes

Mathew L. Thakur and John G. McAfee 922

TEACHING EDITORIAL

Scatter Correction for SPECT

Bernard E. Oppenheim 928